Halozyme Therapeutic...
NasdaqGS:HALO
$ 66,31
$-1,83 (-2,69%)
66,31 $
$-1,83 (-2,69%)
Real-time: 06/02/2026 18:51

News

Morgan Stanley Maintains Overweight on Halozyme Therapeutics, Lowers Price Target to $93

Morgan Stanley analyst Vikram Purohit maintains Halozyme Therapeutics (NASDAQ:HALO) with a Overweight and lowers the price target from $96 to $93.

05/12/2026

Halozyme Therapeutics Affirms FY2026 Adj EPS Guidance of $7.75-$8.25 vs $8.09 Est; Affirms FY2026 Sales Guidance of $1.710B-$1.810B vs $1.760B Est

Halozyme Therapeutics (NASDAQ:HALO) affirms FY2026 Adj EPS guidance from $7.75-$8.25 to $7.75-$8.25 vs $8.09 analyst estimate. Affirms FY2026 sales outlook from $1.710 billion-$1.810 billion to $1.710 billion-$1.810

05/11/2026

Halozyme Company Announced New $1B Share Buyback, Planning At Least $400 M In 2026

05/11/2026

Halozyme Therapeutics Q1 Adj. EPS $1.60 Beats $1.53 Estimate, Sales $376.708M Beat $359.053M Estimate

Halozyme Therapeutics (NASDAQ:HALO) reported quarterly earnings of $1.60 per share which beat the analyst consensus estimate of $1.53 by 4.58 percent. This is a 44.14 percent increase over earnings of $1.11 per share

05/11/2026

Earnings Scheduled For May 11, 2026

05/11/2026

Halozyme Therapeutics Signs License Agreement With GSK For ENHANZE Drug Delivery Technology To Develop, Commercialize Subcutaneous Administration Of Multiple Oncology Targets

Halozyme Therapeutics, Inc. (NASDAQ:HALO) ("Halozyme" or the "Company") today announced the Company entered into a global collaboration and license agreement with GSK. Under the collaboration, GSK has licensed

05/07/2026

Halozyme Appoints Darren Snellgrove As CFO, Effective June, 2026

04/30/2026

HC Wainwright & Co. Maintains Buy on Halozyme Therapeutics, Raises Price Target to $95

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Halozyme Therapeutics (NASDAQ:HALO) with a Buy and raises the price target from $90 to $95.

04/29/2026

Halozyme Therapeutics Signs Collaboration, License Deal With Vertex Pharmaceuticals For Hypercon

Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced its wholly-owned subsidiary, Halozyme Hypercon, Inc., entered into a global exclusive collaboration and license agreement with

04/07/2026
×
Logo
Offer & Services
Features
Pricing
Masters
Trend
Radar
Service & Collaboration
Contact
Help
Affiliate Program
Stock Market Glossary
Company & Legal
Impressum
Privacy Policy
Terms and Conditions

© Copyright 2026 | GROWTH Investing | All Rights Reserved

Important note:

Please note that we do not offer financial services such as investment advice, asset management, or financial brokerage. Our website is solely for providing information and educational content on modern financial strategies and stock analysis. All information presented on this website is for educational purposes and should not be construed as specific investment recommendations. We do not manage client funds and assume no responsibility for individual investment decisions. Each participant is responsible for their own financial decisions and should consult an independent financial advisor if necessary.

The successes, participation figures, and information presented here, provided by Growth Services LLC, are based on our own experiences and those of our clients in the field of stock and chart analysis. They should not be interpreted as an absolute guarantee or a firm promise. Individual success results can vary significantly and depend on numerous factors. The successes presented in our case studies and testimonials reflect the actual results of ourselves and our most dedicated participants and are intended as inspiration, not as a binding commitment. Our offering aims to equip you with the necessary knowledge and skills to perform optimally in the stock market. While we are committed to the success of each individual, we cannot guarantee specific results. Proactive participation and dedication from our clients are essential for success.

This site is not a part of the Facebook, Instagram website or Meta Platforms Inc. Additionally, This site is NOT endorsed by Meta Platforms in any way. FACEBOOK is a trademark of Meta Platforms, Inc.

This website is not affiliated with, endorsed by, or operated by Google LLC. Google is a registered trademark of Google LLC. Our service and offerings are not directly connected to the products or services of Google.